News Home

Monday, October 30, 2023 03:09 PM | InvestorsObserver Analysts

Mentioned in this article

Vaccitech PLC – ADR (VACC) stock has risen 38.89% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Vaccitech PLC – ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VACC!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What’s Happening With VACC Stock Today?

Vaccitech PLC – ADR (VACC) stock is trading at $4.25 as of 2:52 PM on Monday, Oct 30, an increase of $0.61, or 16.76% from the previous closing price of $3.64. The stock has traded between $3.41 and $4.36 so far today. Volume today is less active than usual. So far 225,347 shares have traded compared to average volume of 1,507,188 shares.

To screen for more stocks like Vaccitech PLC – ADR click here.

More About Vaccitech PLC – ADR

Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Its therapeutic programs include VTP-300, VTP-200, VTP-850, and VTP-600. Its current prophylactic programs include VTP-400. In addition, it also co-invented a COVID-19 vaccine candidate with the University of Oxford known as COVID-19 Vaccine AstraZeneca.

Click Here to get the full Stock Report for Vaccitech PLC – ADR stock.

You May Also Like